Nature | Editorial

Translations

عربي

Gene-therapy trials must proceed with caution

The perils of the past must not be allowed to happen again

Article tools

Jesse Gelsinger was 18 and healthy when he died in 1999 during a gene-therapy experiment. He had a condition called ornithine transcarbamylase deficiency (OTC), but it was under control through a combination of diet and medication. Like others with the disorder, Gelsinger lacked a functional enzyme involved in breaking down ammonia, a waste product of protein metabolism that becomes toxic when its levels become too high. The gene therapy that he received used a viral vector to introduce a normal gene for the enzyme.

Gene therapy remains an obvious route to treat OTC. Simply adding the missing gene has been shown to repair metabolism in mice. But the memory of what happened to Gelsinger has slowed progress in gene therapy for any condition.

That memory was firmly on the agenda at a meeting of the US National Institutes of Health’s Recombinant DNA Advisory Committee (RAC) last week. The RAC evaluates proposals to use modified DNA in human trials, and presenting to it were Cary Harding, a medical geneticist at Oregon Health and Science University in Portland, and Sam Wadsworth, chief scientific officer at Dimension Therapeutics in Cambridge, Massachusetts. The duo were proposing the first new trial of gene therapy for OTC.

Harding and the researchers at Dimension argue that the technology and our understanding of physiology have advanced enough since 1999 to try it again in people. Gelsinger died after his body overreacted to the vector used to introduce the OTC gene. Dimension’s therapy uses a different viral vector, called AAV8, which has been tested numerous times in people with other conditions, with few adverse effects.

Such assurances were not enough for the RAC, and particularly not for its bioethicists and historians. Dawn Wooley, a virologist at Wright State University in Dayton, Ohio, pointed out that an RAC panel raised concerns about Gelsinger’s trial in 1995, but decided to let the test go ahead. “We can’t let it happen again, we cannot,” she says.

Perhaps the greatest indication of how Gelsinger’s death haunts the RAC came when one member suggested that the researchers explain in the consent form to be sent to prospective participants that someone had died in a similar study and attracted media attention.

There are some scientific reasons to be careful. AAV8 can cause mild liver toxicity in healthy people, and the steroids used to treat that could lead to complications in people with OTC. With so little known about these effects, the RAC members suggested that the researchers lower the dose to one that is more likely to be safe, even if it is potentially not effective.

After some discussion, the RAC voted unanimously to approve the trial. However, that came with a long list of conditions, including that the treatment first be tested in a second animal species. The researchers disagree with most of the conditions, believing that more expensive animal trials will add nothing. They feel that they are being held to a different standard from most trials.

Dimension still plans to submit an application to the US Food and Drug Administration (FDA) later this year to start a clinical trial. It is unclear how heavily the RAC’s recommendations weigh into FDA decisions, but Wadsworth says that the company will conduct its trials overseas if necessary. “These patients have been waiting a long time,” he says.

He is right. Therapies can be tested in non-human animals only for so long — at some point, volunteers such as Gelsinger must step forward. Yet the echoes of a trial done 17 years ago cannot be easily silenced. In fact, Gelsinger’s name came up several times at the RAC meeting. Researchers from the University of Pennsylvania in Philadelphia had even mentioned him earlier that morning, when proposing the first human trial of CRISPR gene-editing technology as a treatment for cancer. The RAC approved that proposal, but its implication was clear: take care. Avoidable failures could stymie CRISPR research for decades. History must not repeat itself.

Journal name:
Nature
Volume:
534,
Pages:
590
Date published:
()
DOI:
doi:10.1038/534590a

For the best commenting experience, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will see comments updating in real-time and have the ability to recommend comments to other users.

Comments for this thread are now closed.

Comments

2 comments Subscribe to comments

  1. Avatar for Dawn Wooley
    Dawn Wooley
    Some additional information about the Gelsinger death: 1. "After reviewing clinical and postmortem findings as well as other related studies, members of the Working Group concluded, and the RAC concurred, that the research participant’s death most likely resulted from a systemic, Ad vector-induced shock syndrome, due to a cytokine cascade that led to disseminated intravascular coagulation, acute respiratory distress, and multiorgan failure." Reference NIH report: http://osp.od.nih.gov/sites/default/files/adsat_rpt.pdf. 2. Original NIH RAC meeting minutes about the trial (see Dr. Erickson's concerns on pages 25-27): http://osp.od.nih.gov/sites/default/files/124-5-95.pdf 3. Dateline NBC Story about Jesse Gelsinger's death: https://repository.library.georgetown.edu/handle/10822/549358
  2. Avatar for Kenneth Pimple
    Kenneth Pimple
    My memory is imperfect and I was never an expert on Jesse Gelsinger or gene therapy, but I believe a key detail has been overlooked. As I recall, it was determined that Mr. Gelsinger's death was due (at least in part) to a substance used in the procedure that had not been identified as dangerous by either the researchers or the IRB reviewers. It was reported that the researchers' literature search only covered papers that were on the Internet, and that a paper that had not made it to the Internet had described the danger of the substance - the danger was unknown by those who had stopped searching physical journals. (The World Wide Web was invented by Sir Tim Berners in 1989, as I learned from Google.) I remember this because I was a member of the IRB at Indiana University-Bloomington at the time. As some point we required researchers to list all of the sources they had used in their literature search. This may have been a Federal suggestion or policy. I apologize in advance for any errors I may have committed. I am confident that the great bioethicist, Arthur Caplan, remembers better than I.
sign up to Nature briefing

What matters in science — and why — free in your inbox every weekday.

Sign up

Listen

new-pod-red

Nature Podcast

Our award-winning show features highlights from the week's edition of Nature, interviews with the people behind the science, and in-depth commentary and analysis from journalists around the world.